



Aetna Better Health®

Fax completed prior authorization request form to 844-802-1412 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. **Incomplete forms or forms without the chart notes will be returned**

Pharmacy Coverage Guidelines are available at <https://www.aetnabetterhealth.com/illinois-medicaid>

Pulmonary Arterial Hypertension Agents Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently

REQUIRED: Office notes, labs and medical testing relevant to request showing medical justification are required to support diagnosis

Member Information					
Member Name (first & last):		Date of Birth:		Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female	
Member ID:		City:		State:	
				Height:	
				Weight:	
Prescribing Provider Information					
Provider Name (first & last):		Specialty:		NPI#	
Office Address:		City:		State:	
				DEA#	
Office Contact:		Office Phone		Office Fax:	
Dispensing Pharmacy Information					
Pharmacy Name:		Pharmacy Phone:		Pharmacy Fax:	
Requested Medication Information					
Preferred Agents:	<input type="checkbox"/> Sildenafil	<input type="checkbox"/> Epoprostenol	<input type="checkbox"/> Letairis	<input type="checkbox"/> Tracleer	<input type="checkbox"/> Flolan
	<input type="checkbox"/> Revatio suspension				
Non-Preferred Agents:	<input type="checkbox"/> tadalafil	<input type="checkbox"/> Adempas	<input type="checkbox"/> Orenitram	<input type="checkbox"/> Revatio	<input type="checkbox"/> Upravi
	<input type="checkbox"/> Remodulin	<input type="checkbox"/> Opsumit	<input type="checkbox"/> Tyvaso	<input type="checkbox"/> Ventavis	<input type="checkbox"/> Veletri
	<input type="checkbox"/> Revatio	<input type="checkbox"/> Treprostinil	<input type="checkbox"/> Other, please specify:		
Are there any contraindications to formulary medications? If yes, please specify:				<input type="checkbox"/> Yes	<input type="checkbox"/> No
				<input type="checkbox"/> New request	<input type="checkbox"/> Continuation of therapy request
For continuation of therapy requests ONLY (check that apply):	<input type="checkbox"/> Response to therapy	<input type="checkbox"/> Maintained OR achieved low risk profile (improvement in 6 MWD, functional class OR reducing time to clinical worsening)			
Directions for Use:	Strength:		Dosage Form:		
	Quantity:	Day Supply:	Duration of Therapy/Use:		
What medication(s) has member tried and failed for this diagnosis? Please specify:					
Medication request is NOT for an FDA- approved, or compendia-supported diagnosis (circle one): Yes No			Diagnosis:		ICD-10 Code:
Turn-Around Time for Review					
<input type="checkbox"/> Standard – (24 hours)		<input type="checkbox"/> Urgent – If waiting 24 hours for a standard decision could seriously harm life, health, or ability to regain maximum function, you can ask for an expedited decision.			
		Signature: _____			
Clinical Information - General Authorization Criteria					
Is there evidence of right heart catheterization with mPAP ≥25mm Hg?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Is diagnosis of PAH WHO Group I with Functional Class II to IV symptoms?	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Did member have a negative vasoreactivity test?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Did member have a contraindication to vasoreactivity test?	<input type="checkbox"/> Yes	<input type="checkbox"/> No

Was there a positive vasoreactivity test with inadequate response OR intolerance to ONE calcium channel blocker?			<input type="checkbox"/> Yes	<input type="checkbox"/> No	Is there a contraindication to use of a calcium channel blocker?		<input type="checkbox"/> Yes	<input type="checkbox"/> No
Is member pregnant?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A	Will there be concurrent use of nitrate OR nitric oxide donors such as isosorbide mononitrate, isosorbide dinitrate OR nitroglycerin?			<input type="checkbox"/> Yes	<input type="checkbox"/> No
Does member have hepatic impairment (Child Pugh class C)?			<input type="checkbox"/> Yes	<input type="checkbox"/> No	Does member have pulmonary veno-occlusive disease?		<input type="checkbox"/> Yes	<input type="checkbox"/> No
Does member have HF with severe left ventricular dysfunction?							<input type="checkbox"/> Yes	<input type="checkbox"/> No
Additional Drug Specific Criteria								
<input type="checkbox"/> Revatio Oral Suspension				<input type="checkbox"/> Tadalafil				
Was documentation presented to support inability to swallow AND necessity of brand suspension formulation?			<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was documentation presented to support trial AND failure OR intolerance with sildenafil?		<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Adempas								
Is diagnosis of WHO PAH Group I with Functional Class II to IV symptoms?				<input type="checkbox"/> Yes		<input type="checkbox"/> No		
Member had trial AND failure with ALL preferred oral agents from each class (check that apply):				(PDE-5) inhibitor		Endothelin Receptor Antagonist		
				<input type="checkbox"/> Sildenafil		<input type="checkbox"/> Tracleer tablets		
				<input type="checkbox"/> Tadalafil		<input type="checkbox"/> Letairis	<input type="checkbox"/> Opsumit	
Is diagnosis for Chronic Thromboembolic Pulmonary Hypertension WHO Group IV?			<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was there recurrent OR persistent Chronic Thromboembolic Pulmonary Hypertension after surgical treatment?		<input type="checkbox"/> Yes	<input type="checkbox"/> No
Does member have inoperable Chronic Thromboembolic Pulmonary Hypertension?							<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Upravi				<input type="checkbox"/> Orenitram				
Does member have severe hepatic impairment (Child-Pugh class C)?				<input type="checkbox"/> Yes		<input type="checkbox"/> No		
WHO Class II and III symptoms: Member had trial AND failure with ALL preferred ORAL agents from each class (check that apply):				(PDE-5) inhibitor		Endothelin Receptor Antagonist		
				<input type="checkbox"/> Sildenafil		<input type="checkbox"/> Tracleer tablets		
				<input type="checkbox"/> Tadalafil		<input type="checkbox"/> Letairis	<input type="checkbox"/> Opsumit	
WHO Class IV symptoms: Member had trial AND failure with ONE Prostacyclin:				Prostacyclin Analog				
				<input type="checkbox"/> Epoprostenol				
<input type="checkbox"/> Tyvaso		<input type="checkbox"/> Ventavis		<input type="checkbox"/> Remodulin			<input type="checkbox"/> treprostinil	
<input type="checkbox"/> Tyvaso AND Ventavis: Does member have Functional Class III-IV symptoms?			<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> Remodulin: Does member have Functional Class II-IV?		<input type="checkbox"/> Yes	<input type="checkbox"/> No
WHO Class II and III symptoms: Trial AND failure with ALL preferred oral agents from each class:				(PDE-5) inhibitor		Endothelin Receptor Antagonist		
				<input type="checkbox"/> sildenafil		<input type="checkbox"/> Tracleer tablets		
				<input type="checkbox"/> tadalafil		<input type="checkbox"/> Letairis	<input type="checkbox"/> Opsumit	
WHO Class IV symptoms: Trial AND failure with ONE Prostacyclin:				Prostacyclin Analog				
				<input type="checkbox"/> Epoprostenol				
Additional information the prescribing provider feels is important to this review. Please specify below or submit medical records.								

[Empty box for signature and notes]

Signature affirms that information given on this form is true and accurate and reflects office notes.

Prescribing Provider's Signature: _____ **Date:** _____

Please note: Incomplete forms or forms without the chart notes will be returned

Office notes, labs, and medical testing relevant to the request that show medical justification are required.
Standard turnaround time is 24 hours. You can call 866-329-4701 to check the status of a request.